Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.1200
- TODAY'S CHANGE (%)-0.0300 (-0.7229%)
- Bid / Lots4.1100/ 3
- Ask / Lots4.1200/ 1
- Open / Previous Close4.2000 / 4.1500
- Day Range
- 52 Week Range
- Volume72,713
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 3797 | 4.2 |
| 09:34 ET | 1600 | 4.12 |
| 09:36 ET | 262 | 4.1274 |
| 09:38 ET | 583 | 4.17 |
| 09:39 ET | 339 | 4.17 |
| 09:41 ET | 1015 | 4.13 |
| 09:43 ET | 1056 | 4.15 |
| 09:45 ET | 6999 | 4.1301 |
| 09:48 ET | 100 | 4.16 |
| 09:54 ET | 12930 | 4.1001 |
| 09:57 ET | 2621 | 4.12 |
| 10:01 ET | 4683 | 4.115 |
| 10:03 ET | 14804 | 4.11 |
| 10:06 ET | 1350 | 4.0901 |
| 10:10 ET | 2704 | 4.1329 |
| 10:12 ET | 200 | 4.15 |
| 10:14 ET | 2400 | 4.1525 |
| 10:15 ET | 3914 | 4.13 |
| 10:17 ET | 300 | 4.12 |
| 10:19 ET | 100 | 4.11 |
| 10:21 ET | 6005 | 4.1136 |
Jun 20, 2024
DJ Mereo BioPharma Group Is Maintained at Outperform by Leerink Partners, from 8:19AM ET on Thursday Jun 20, 2024 by Dow Jones
8:19AM ET on Thursday Jun 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 634.1M | -12.8x | --- |
Immunome Inc | 849.2M | -2.6x | --- |
Perspective Therapeutics Inc | 831.4M | -7.6x | --- |
Stoke Therapeutics Inc | 759.9M | -6.3x | --- |
AnaptysBio Inc | 893.6M | -5.4x | --- |
Dianthus Therapeutics Inc | 851.1M | -9.1x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $634.1M |
|---|---|
Revenue (TTM) | $10.3M |
Shares Outstanding | 152.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-0.32 |
Book Value | $0.46 |
P/E Ratio | -12.8x |
Price/Sales (TTM) | 61.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
